About Pokeacell
Pokeacell is a company based in Copenhagen (Denmark) founded in 2020 by Soren Nyboe Jakobsen, Anne Reker Cordt, and Sine Hadrup. Pokeacell has raised $1.48 million across 1 funding round from investors including BioInnovation Institute. The company has 8 employees as of March 31, 2022. Pokeacell operates in a competitive market with competitors including Philogen, Aura Biosciences, OnQuality, SkinJect and Therakos, among others.
- Headquarter Copenhagen, Denmark
- Employees 8 as on 31 Mar, 2022
- Founders Soren Nyboe Jakobsen, Anne Reker Cordt, Sine Hadrup
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pokeacell Aps
-
Annual Revenue
Not available
-
Net Profit
-$622.67 K (USD)0as on Dec 31, 2022
-
EBITDA
-$730.61 K (USD)0as on Dec 31, 2022
-
Total Equity Funding
$1.48 M (USD)
in 1 rounds
-
Latest Funding Round
$1.48 M (USD), Seed
Mar 31, 2020
- Investors
-
Employee Count
8
as on Mar 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Pokeacell
Pokeacell has successfully raised a total of $1.48M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.48 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pokeacell
Pokeacell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BioInnovation Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Pokeacell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pokeacell
Investment portfolio details for Pokeacell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pokeacell
Detailed financials for Pokeacell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pokeacell Comparisons
Peer comparison for Pokeacell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pokeacell
Pokeacell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Philogen, Aura Biosciences, OnQuality, SkinJect and Therakos, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for angiogenesis-related cancers and disorders.
|
|
| Locked | Locked | Locked |
Therapies are developed to target and destroy cancer cells selectively.
|
|
| Locked | Locked | Locked |
Therapeutics for skin cancers and related reactions are developed.
|
|
| Locked | Locked | Locked |
Dissolvable microneedle patches for non-melanoma skin cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therakos is focused on photopheresis systems for CTCL treatment.
|
Detailed competitors of Pokeacell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pokeacell
Complete news archive for Pokeacell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pokeacell
Pokeacell was founded in 2020.
Pokeacell is headquartered in Copenhagen, Denmark.
Anne Reker Cordt is the current CEO of Pokeacell. They have also founded this company.
Pokeacell is a funded company, having raised a total of $1.48M across 1 funding round to date.
As of Mar 31, 2022, the latest employee count at Pokeacell is 8.
Pokeacell was founded in 2020 and is based in Copenhagen, Denmark. Operations focus on the biotechnology sector, where T cell therapeutic solutions for cancer are developed. Poke-101, a product responding to shared melanoma antigens via ImmPACT activation technology, is in preclinical development for treating skin conditions such as melanoma. Poke-102, targeting virus antigens in Merkel Cell Carcinoma, is also at the preclinical stage.
Pokeacell's top competitors include Philogen, Aura Biosciences and Therakos.
Pokeacell has 1 investor. Key investors include BioInnovation Institute.